Zobrazeno 1 - 10
of 65
pro vyhledávání: '"Peter E. Pool"'
Autor:
Peter E. Pool
Publikováno v:
Clinical Cardiology. 23:18-23
From early research, investigators understood that the dose of diltiazem required for the treatment of hypertension (commonly 360 mg/day) was greater than that required for the treatment of angina (commonly 240 mg/day). Nonetheless, studies of recent
Publikováno v:
The American Journal of Cardiology. 80:421-425
Myocardial ischemia occurs frequently during daily life and has a circadian pattern similar to that reported for myocardial infarction and sudden death. Because of the increased risk of myocardial ischemia in the morning hours, it has been suggested
Publikováno v:
Clinical Cardiology. 17:484-488
This multicenter, open-label, single crossover study examined 195 patients taking an immediate-release diltiazem tablet as chronic stable angina therapy to determine if apparently logical methods of converting them to an extended-release, once-daily
Autor:
Peter E. Pool, F. Wilford Germino, Michael S. Willett, Juan Lastra, Susan Wallace, Dennis Cryer, Bruce Spinowitz, Jacqueline de Silva, William Benjamin Smith, Henry Punzi, Donna J. Mills
Publikováno v:
Current Therapeutic Research. 54:469-475
To evaluate the cough profile of fosinopril in treated hypertensive patients with active cough associated with angiotensin-converting enzyme (ACE) inhibitors other than fosinopril, a 7-week, prospective, open-label study was undertaken. This consiste
Autor:
Peter E. Pool, Jang B. Singh, Melvin D. Cheitlin, Sunil K. Das, Richard C. Pasternak, Prakash C. Deedwania
Publikováno v:
Clinical Cardiology. 16:599-602
Although calcium antagonists form a mainstay of therapy in patients with angina pectoris, the currently available agents have significant limitations. Nifedipine, diltiazem, and verapamil are all high-clearance agents with significant hepatic extract
Autor:
Peter E. Pool
Publikováno v:
Cardiovascular Drugs and Therapy. 4:573-577
This review summarizes the data from all the studies conducted in the United States and Europe that have evaluated the efficacy of encainide in patients with a variety of supraventricular arrhythmias. Using clinical criteria of efficacy, encainide wa
Autor:
Peter E. Pool
Publikováno v:
Cardiology. 90(1)
Traditionally, the pathophysiology of heart failure was viewed as a derangement in hemodynamic factors. Impairment in cardiac function resulted in decreased cardiac output and end-organ hypoperfusion triggering compensatory increases in heart rate, b
Autor:
Peter E. Pool
Publikováno v:
Clinical therapeutics. 19
Progressive heart disease after the onset of left ventricular dysfunction has typically been attributed to hemodynamic factors. As left ventricular function declines, decreased cardiac output and tissue hypoperfusion lead to compensatory increases in
Autor:
Peter E. Pool
Publikováno v:
Progress in cardiovascular diseases. 36(1)